Elected: 2023
Discipline: Cell and Molecular Biology
Mrs Angela Scott
TC BioPharm Scotland
Born and raised in Edinburgh, Angela Scott has a life-long passion for biological-sciences.
After graduating, her career commenced at the Imperial Cancer Research Fund, Edinburgh.
Moving to industry Angela became fascinated by the therapeutic potential of stem cells, working in Singapore and Scotland as part of the ground-breaking team that cloned Dolly the Sheep. Having grown cells used to clone the first ever mammal, she is affectionately referred to as the ‘mother of Dolly’.
A GlobalScot with over forty years’ in cutting edge cell therapy, Angela is considered a key opinion leader whose experience transcends multiple commercial disciplines. Direct expertise includes product development, building/running GMP facilities, distribution logistics, quality, regulatory and process/product scale-up.
Angela has contributed to the transition of several cell therapy products from concept to late-stage clinical trial. As founder and COO of TC BioPharm (TCBP – Nasdaq), Angela established the Scottish company as a global-leader in T cell therapy, successfully conducting multi-national studies on patients with several different solid and liquid cancers.
After graduating, her career commenced at the Imperial Cancer Research Fund, Edinburgh.
Moving to industry Angela became fascinated by the therapeutic potential of stem cells, working in Singapore and Scotland as part of the ground-breaking team that cloned Dolly the Sheep. Having grown cells used to clone the first ever mammal, she is affectionately referred to as the ‘mother of Dolly’.
A GlobalScot with over forty years’ in cutting edge cell therapy, Angela is considered a key opinion leader whose experience transcends multiple commercial disciplines. Direct expertise includes product development, building/running GMP facilities, distribution logistics, quality, regulatory and process/product scale-up.
Angela has contributed to the transition of several cell therapy products from concept to late-stage clinical trial. As founder and COO of TC BioPharm (TCBP – Nasdaq), Angela established the Scottish company as a global-leader in T cell therapy, successfully conducting multi-national studies on patients with several different solid and liquid cancers.